In preclinical models, PAHSA treatment improves glucose tolerance, enhances insulin signaling, and lowers inflammatory markers, suggesting that these lipids may help prevent or reverse pancreatic β-cell dysfunction in diabetes [96]. The gene discussed is INS; the disease is diabetes mellitus.